Altria
MO
$68.33
+0.57%
Altria Group, Inc. is a leading U.S. tobacco company that manufactures and sells cigarettes, smokeless tobacco, cigars, and nicotine pouches, operating primarily in the consumer defensive sector. It is the dominant player in the U.S. cigarette market with its flagship Marlboro brand holding a 40% share, and it also holds significant stakes in Anheuser-Busch InBev and Cronos, positioning it as a diversified consumer staples giant. The current investor narrative centers on Altria's transition toward reduced-risk products, including its Njoy vaping acquisition and On nicotine pouches, while navigating declining cigarette volumes and regulatory pressures. Recent news highlights a Q2 earnings miss and lowered guidance, which has sparked debate about the sustainability of its high dividend and the success of its smoke-free strategy.…
MO
Altria
$68.33
Related headlines
Investment Opinion: Should I buy MO Today?
Based on the analysis, Altria is rated a Hold. The consensus analyst recommendation is 'hold' with an average target price of $70.64, implying a modest 3.4% upside from the current price of $68.33. The thesis is that Altria offers a high dividend yield and low valuation, but near-term earnings headwinds and structural volume declines limit upside potential. Supporting evidence includes a forward PE of 11.6x, Q1 revenue growth of 20.1%, a dividend yield of 7.2%, and strong free cash flow of $8.6 billion. However, the Q2 earnings miss and guidance cut suggest near-term challenges. The rating would upgrade to Buy if the stock drops below $60 (yield >8%) or if smoke-free product growth accelerates, and downgrade to Sell if the dividend is cut or volumes decline faster than expected. Overall, the stock is fairly valued relative to its history, but undervalued relative to the broader market.
Sign up to view all
MO 12-Month Price Forecast
The AI assessment is neutral, reflecting a balanced risk/reward profile. Altria's low valuation and high yield provide downside support, but the recent earnings miss and structural volume declines cap upside. The stock is likely to trade in a range, with the dividend acting as a key support. An upgrade to bullish would require evidence of accelerating smoke-free growth and stable cigarette volumes, while a downgrade to bearish would be triggered by a dividend cut or significant regulatory action.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $70.64 and implied upside of +3.4% versus the current price.
Average Target
$70.64
0 analysts
Implied Upside
+3.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$59 - $82
Analyst target range
Altria is covered by 11 analysts, with a consensus recommendation of 'hold' and a mean rating of 2.64 (where 1 is strong buy and 5 is sell). The average target price is $70.64, implying a modest upside of 3.4% from the current price of $68.33. The distribution of ratings includes 4 buys, 5 holds, and 2 underweights, indicating a cautious sentiment. The high target of $82.00 suggests potential upside of 20% if the company successfully executes its smoke-free strategy and stabilizes cigarette volumes, while the low target of $59.00 implies a downside of 13.7% if regulatory pressures and volume declines intensify. Recent ratings actions have been mixed, with UBS reiterating a Buy in July 2026 and Barclays maintaining an Underweight, reflecting the uncertainty surrounding Altria's transition.
Bulls vs Bears: MO Investment Factors
Altria presents a classic income-investing dilemma: a high dividend yield and attractive valuation versus structural volume declines and regulatory overhang. The bull case rests on strong Q1 revenue growth, a dominant market position, and a compelling forward PE of 11.6x, while the bear case highlights the Q2 miss, declining volumes, and a payout ratio that leaves no room for error. Currently, the bearish evidence is slightly stronger given the recent earnings miss and guidance cut, but the stock's low valuation and high yield provide a margin of safety. The key tension is whether Altria can successfully transition to reduced-risk products (Njoy, On) to offset cigarette declines; if it fails, the dividend may become unsustainable, but if it succeeds, the stock could re-rate higher.
Bullish
- Strong Q1 Revenue Growth: Q1 2026 revenue surged 20.1% YoY to $5.428 billion, driven by smokeable products at $4.758 billion and smokeless at $669 million. This robust growth outpaces the broader consumer staples sector and demonstrates pricing power despite volume declines.
- High Dividend Yield of 7.2%: Altria offers a dividend yield of 7.2%, well above the S&P 500 average of ~1.3%. The payout ratio is 100.2%, indicating the dividend is fully covered by earnings, providing a strong income stream for investors.
- Attractive Forward Valuation: The forward PE of 11.6x is below the trailing PE of 14.0x, implying expected earnings growth. This discount to the broader market (S&P 500 forward PE ~20x) suggests the stock is undervalued relative to its earnings potential.
- Dominant Market Position: Marlboro holds a 40% share of the U.S. cigarette market, providing significant pricing power and brand loyalty. This moat supports stable cash flows and the ability to fund the high dividend.
Bearish
- Q2 Earnings Miss and Guidance Cut: Altria's Q2 2026 earnings missed expectations, and the company lowered its guidance midpoint, signaling near-term headwinds. This has led to a sharp stock decline of 8.7% in one day, reflecting investor disappointment.
- Declining Cigarette Volumes: Cigarette volumes continue to decline industry-wide, and Altria's smokeable product volumes are falling. This structural decline pressures revenue growth and requires successful transition to reduced-risk products to offset.
- High Payout Ratio Limits Growth: With a payout ratio of 100.2%, Altria is returning nearly all earnings to shareholders, leaving little room for reinvestment in growth initiatives or debt reduction. This could constrain future dividend increases.
- Regulatory and Litigation Risks: The tobacco industry faces ongoing regulatory pressures, including potential FDA rules on nicotine levels and menthol bans. Litigation costs and settlement payments could impact cash flows and profitability.
MO Technical Analysis
Altria's stock has demonstrated a strong recovery over the past year, with a 1-year price change of +10.3%, though it has pulled back from its 52-week high of $77.06. As of July 31, 2026, the stock trades at $68.33, which is approximately 88.7% of its 52-week range (calculated from the low of $54.70 to the high of $77.06). This positioning near the upper end of the range suggests that while the stock has momentum, it may be approaching overbought territory, especially after a recent sharp decline from the high.
Beta
0.49
0.49x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$55-$77
Price range past year
Annual Return
+10.3%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | -4.5% | +0.3% |
| 3m | -8.3% | +4.0% |
| 6m | +10.2% | +8.3% |
| 1y | +10.3% | +20.2% |
| ytd | +19.2% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Altria's revenue has shown robust growth, with the most recent quarter (Q1 2026) reporting revenue of $5.428 billion, a 20.1% year-over-year increase. This growth is driven by strong performance in smokeable products, which generated $4.758 billion in revenue, and smokeless products at $669 million. However, the company's net income of $2.183 billion in Q1 2026 represents a significant improvement from the prior year's Q1 net income of $1.077 billion, indicating accelerating profitability. The gross margin for Q1 2026 was 64.6%, up from 71.9% in Q1 2025, but this is partly due to a one-time gain in the prior year. Operating margin stood at 54.5%, reflecting the company's pricing power and cost discipline.
Quarterly Revenue
$5.4B
2026-03
Revenue YoY Growth
+20.1%
YoY Comparison
Gross Margin
64.6%
Latest Quarter
Free Cash Flow
$8.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
Given Altria's positive net income, the price-to-earnings (PE) ratio is the primary valuation metric. The trailing PE is 14.0x, while the forward PE is 11.6x, indicating that the market expects earnings growth. This forward discount suggests that analysts anticipate higher future earnings, likely driven by cost savings and growth in reduced-risk products. The stock's PEG ratio is negative at -0.38, which is unusual and reflects the negative earnings growth rate used in the calculation, but this is not a reliable indicator given the company's positive growth trajectory.
PE
14.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~13x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Altria carries significant debt, with a debt-to-equity ratio of -7.34 (negative equity due to buybacks), and interest expenses of $258 million in Q1 2026. The payout ratio of 100.2% means the dividend consumes all net income, leaving little cushion for earnings shortfalls. Revenue concentration in the declining cigarette market is a major risk, as smokeable products account for ~88% of revenue. The company's operating margin of 54.5% is strong, but any volume decline could compress margins if fixed costs cannot be reduced. Free cash flow of $8.6 billion provides some buffer, but it is not immune to regulatory fines or litigation settlements.
FAQ
The key risks for Altria include: 1) Regulatory risk - potential FDA regulations on menthol and nicotine levels could significantly impact cigarette sales. 2) Volume decline risk - structural decline in cigarette consumption could erode revenue and cash flows. 3) Dividend risk - with a payout ratio of 100.2%, any earnings shortfall could force a dividend cut. 4) Litigation risk - ongoing tobacco litigation could result in large settlements. The most severe risk is a combination of regulatory action and volume decline, which could lead to a dividend cut and a sharp stock price drop.
The 12-month forecast for Altria is a base case price of $65-72, with a 50% probability, assuming stable performance and continued dividend payments. The bull case targets $75-82 (25% probability) if smoke-free products gain traction, while the bear case targets $55-60 (25% probability) if regulatory and volume pressures intensify. The most likely scenario is the base case, with the stock trading in a range and the dividend providing support. The average analyst target is $70.64, implying modest upside.
Altria's trailing PE of 14.0x and forward PE of 11.6x are below the S&P 500 average of around 20x, suggesting the stock is undervalued relative to the broader market. Compared to its own history, the current PE is in line with its 5-year average of around 12-15x. The stock also trades at a discount to its peer group, with a PS ratio of 4.8x. The market appears to be pricing in modest earnings growth and a stable dividend, but not a significant re-rating. Overall, MO is fairly valued to slightly undervalued, offering a margin of safety for income investors.
Altria offers a compelling dividend yield of 7.2% and a forward PE of 11.6x, which is attractive relative to the market. However, the recent Q2 earnings miss and declining cigarette volumes introduce uncertainty. The analyst consensus is 'hold' with an average target price of $70.64, implying only 3.4% upside. For income-focused investors with a long-term horizon, MO can be a good buy at current levels, especially if the dividend is sustainable. But for growth-oriented investors, the limited upside and structural risks may make it less appealing. The biggest downside risk is a dividend cut, which could occur if volumes decline faster than expected.
Altria is best suited for long-term investment, particularly for income-focused investors. The stock has a beta of 0.49, indicating low volatility, and offers a high dividend yield of 7.2%. However, the company faces structural challenges that could limit capital appreciation. Short-term trading is possible, but the stock's low volatility and lack of catalysts make it less attractive for traders. A minimum holding period of 3-5 years is recommended to capture the dividend income and allow the transition strategy to unfold. Investors should monitor the dividend sustainability and regulatory developments closely.